NASDAQ: NAYANaya Biosciences Inc Stock
$2.74+0.40 (+17.09%)
Updated Mar 21, 2025
NAYA Price
$2.74
Fair Value Price
N/A
Market Cap
$1.13M
52 Week Low
$1.94
52 Week High
$42.00
P/E
-0.28x
P/B
-48.34x
P/S
0.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.23M
Earnings
-$7.47M
Gross Margin
42.4%
Operating Margin
-102.87%
Profit Margin
-119.9%
Debt to Equity
-730.95
Operating Cash Flow
-$3M
Beta
1.16
Next Earnings
Apr 14, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NAYA Overview
INVO Bioscience Incorporated is a commercial-stage company developing tassisted reproductive technologies intended to make fertility care accessible to people around the world. The company's flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place within the woman's body. Its treatment solution is an intravaginal culture technique which incubates both oocytes and sperm during fertilization and early embryo development. INVO Bioscience was founded in 2007 and is headquartered in Sarasota, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NAYA's potential to beat the market
- NAYA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NAYA
RankedUnranked of 109
RankedUnranked of 109
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.65 | A | |
| $24.73 | A | |
| $13.29 | A |
Be the first to know about important NAYA news, forecast changes, insider trades & much more!
NAYA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAYA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NAYA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NAYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NAYA due diligence checks available for Premium users.
Valuation
NAYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.28x
Industry
42.4x
Market
31.55x
NAYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-48.34x
Industry
3.95x
NAYA's financial health
Profit margin
Revenue
$1.4M
Net Income
-$1.6M
Profit Margin
-113.8%
NAYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAYA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.0M
Liabilities
$17.0M
Debt to equity
-730.95
NAYA's short-term liabilities ($8.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAYA's long-term liabilities ($8.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAYA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$640.8k
Investing
$0.0
Financing
$169.5k
NAYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAYA vs Medical Device Stocks
Naya Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.